U.S. Point-of-Care Testing Devices Market

Market Outlook

By 2035, the U.S. Point-of-Care Testing Devices Market is expected to reach approximately USD 35.20 billion, expanding at a CAGR of 9.20% during the forecast period 2026-2035. The market was valued at USD 14.60 billion in 2025, with historical analysis from 2021 to 2024. Values in this report are expressed in USD billions. The forecast reflects a broad device-and-consumables scope covering professional point-of-care analyzers, single-use cartridges, rapid test kits, connected meters, near-patient molecular platforms, and selected home-use diagnostic systems that directly support clinical decision-making.

The U.S. point-of-care testing devices industry sits at the intersection of laboratory medicine, frontline care delivery, consumer diagnostics, and digital health. Demand is being shaped by the need to move actionable testing closer to emergency departments, intensive care units, physician offices, urgent care centers, pharmacies, community health centers, ambulances, long-term care facilities, and the home. Point-of-care testing is strategically valuable because it compresses the interval between specimen collection, result availability, treatment selection, and patient disposition. In high-volume settings, the economic value is not limited to the test itself; it includes reduced send-out testing, fewer return visits, faster isolation decisions, shorter emergency department dwell time, more efficient bed use, and improved antimicrobial or antiviral stewardship.

The market is moving beyond basic glucose meters, pregnancy tests, and visual-read lateral-flow assays toward integrated platforms capable of multiplex respiratory testing, compact molecular amplification, blood gas and electrolyte analysis, cardiac marker testing, coagulation monitoring, HbA1c testing, lipid assessment, infectious disease screening, and cloud-connected quality management. U.S. buyers increasingly prefer systems that combine a compact footprint with a broad assay menu, low hands-on time, automated calibration, operator lockout, electronic medical record connectivity, remote fleet administration, and traceable quality-control records. These requirements are pushing manufacturers to compete on workflow architecture and informatics as much as on analytical performance.

The historical market was elevated at USD 12.18 billion in 2021 because of pandemic-related rapid testing demand, moderated to USD 11.72 billion in 2022 as emergency purchasing normalized, and then recovered to USD 12.46 billion in 2023 and USD 13.58 billion in 2024. The market reached USD 14.60 billion in 2025 as non-COVID respiratory testing, professional glucose testing, near-patient molecular diagnostics, blood gas analysis, cardiac and coagulation testing, and consumer self-testing generated a more diversified growth base. This transition is important because the market is no longer dependent on a single infectious-disease event; it is increasingly supported by chronic disease prevalence, outpatient expansion, test-to-treat models, and the operational needs of decentralized healthcare delivery.

Introduction

According to the U.S. Point-of-Care Testing Devices Market Report, the market is supported by a uniquely large and fragmented testing environment. The United States has approximately 320,000 CLIA-regulated laboratory entities, and a substantial share of decentralized sites operate under certificates that permit waived testing. The care-delivery base also includes about 6,100 hospitals, more than 907,000 staffed beds, and over 35.6 million annual hospital admissions. This infrastructure creates recurring demand for bedside, departmental, ambulatory, and near-patient testing systems that can function outside a central laboratory while still meeting documentation, quality, and connectivity expectations.

The U.S. point-of-care testing devices market is not a single product category. It includes capital-light disposable tests, reader-based immunoassays, handheld blood analyzers, benchtop molecular systems, connected glucose meters, blood gas systems, portable coagulation devices, urinalysis platforms, pregnancy and fertility tests, and compact chemistry or hematology instruments. Revenue is generated through a mix of instrument placements, reagent rental arrangements, consumable pull-through, distribution contracts, direct-to-consumer sales, and enterprise agreements with health systems. The recurring nature of cartridges, strips, cassettes, controls, and quality-management services gives the market a durable installed-base model.

The clinical need is substantial. The U.S. had an estimated 40.1 million people with diagnosed or undiagnosed diabetes in 2023 and approximately 115.2 million adults with prediabetes. Respiratory disease also creates large seasonal testing volumes: the 2024-2025 influenza season was associated with tens of millions of symptomatic illnesses and medical visits. In sexual health, more than 2.4 million nationally notifiable cases of chlamydia, gonorrhea, and syphilis were reported in 2023. These disease pools support repeated demand for glucose, HbA1c, respiratory, STI, pregnancy, coagulation, blood gas, cardiac marker, and other rapid tests across professional and home settings.

Point-of-care testing is also closely linked to the economics of access. HRSA-funded health centers serve more than 32 million people through nearly 1,400 health centers and more than 16,200 service sites, many of which manage high volumes of diabetes, pregnancy, infectious disease, and primary-care testing. Urgent care, retail clinics, employer clinics, mobile health programs, and pharmacy-based services further expand the number of locations where a rapid result can influence an immediate care decision. The commercial opportunity therefore depends on more than hospital capital budgets; it also depends on whether devices fit the staffing, training, throughput, and reimbursement realities of smaller decentralized sites.

From 2026 to 2035, the central strategic theme will be the conversion of point-of-care testing from a collection of isolated devices into a connected diagnostic network. Health systems will increasingly standardize devices across multiple care settings, manage operator competency remotely, compare point-of-care results with core-laboratory data, and use test utilization data to guide formulary decisions. Manufacturers that can integrate analyzers, consumables, middleware, cybersecurity, quality controls, service, and reimbursement support will be better positioned than vendors selling single tests without a scalable operating model.

Key Market Drivers: What’s Fueling the U.S. Point-of-Care Testing Devices Market Boom?

The first major driver is the scale of chronic disease monitoring. Diabetes remains the largest recurring point-of-care testing opportunity because glucose testing is frequent, clinically actionable, and performed across hospitals, physician offices, long-term care facilities, emergency transport, and the home. The large population with diabetes and prediabetes sustains demand for professional blood glucose meters, test strips, lancets, ketone testing, HbA1c analyzers, and connected monitoring systems. The commercial opportunity is shifting from stand-alone meters toward interoperable platforms that support patient identification, dosing workflows, wireless data capture, strip-lot management, and enterprise quality oversight.

A second driver is the continuing respiratory and infectious disease burden. Influenza, COVID-19, RSV, streptococcal infection, sexually transmitted infections, hepatitis, and other communicable diseases require rapid differentiation because clinical symptoms frequently overlap. The 2024-2025 influenza season alone produced an estimated 43 million to 73 million symptomatic illnesses and 19 million to 32 million medical visits. This level of seasonal demand supports antigen and molecular testing in urgent care, pediatric clinics, emergency departments, pharmacies, and homes. Multiplex tests that identify more than one pathogen from a single specimen can improve treatment selection and reduce repeat testing.

A third driver is the migration of care away from centralized hospital settings. Physician offices, urgent care centers, ambulatory clinics, retail health locations, community health centers, long-term care facilities, home health agencies, and employer clinics need testing systems that can operate with limited laboratory staffing. CLIA-waived devices are especially important because they lower the operational barrier to testing, although buyers still require training, quality-control discipline, and documentation. The broader availability of waived molecular and immunoassay systems is expanding the addressable market for high-value testing outside traditional laboratories.

A fourth driver is hospital workflow economics. Point-of-care testing can create measurable value when a result changes immediate management, such as anticoagulation adjustment, respiratory isolation, insulin dosing, sepsis assessment, electrolyte correction, pregnancy status before imaging or medication, or triage of suspected cardiac events. Hospitals evaluate these devices through total episode economics rather than reagent price alone. A higher-priced cartridge may still be preferred if it reduces transport time, accelerates treatment, supports faster discharge, improves operating room or emergency department throughput, or prevents a second patient encounter.

A fifth driver is the expansion of test-to-treat pathways. Rapid testing has greater commercial value when it is linked to an immediate prescription, procedure, referral, or infection-control action. Respiratory antivirals, antibiotics for confirmed bacterial infections, hepatitis C linkage to treatment, anticoagulation management, and diabetes medication decisions all benefit from shorter diagnostic turnaround. Point-of-care devices that provide sufficient analytical confidence for same-visit decisions are therefore gaining stronger clinical and economic relevance than screening tools that require routine confirmatory send-out testing.

A sixth driver is consumer acceptance of self-testing and connected home care. The pandemic normalized at-home specimen collection, visual-read testing, app-supported interpretation, and direct access to diagnostic information. The market is now broadening into combined respiratory tests, glucose and ketone testing, fertility testing, HIV self-testing, and other home-use formats. Growth will depend on clear instructions, affordable repeat use, reliable result interpretation, linkage to professional care, and digital support that helps consumers understand when to retest or seek treatment.

A seventh driver is the U.S. reimbursement and regulatory ecosystem. Medicare and commercial payers reimburse many clinical diagnostic laboratory tests through established coding and fee-schedule mechanisms, while CLIA categorization determines where testing may be performed. Products that achieve CLIA waiver, secure appropriate CPT or HCPCS coding, and demonstrate clinical utility have a stronger pathway to decentralized adoption. Manufacturers increasingly need reimbursement evidence, health-economic models, and utilization protocols in addition to FDA clearance.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. point-of-care testing devices market is increasingly focused on delivering laboratory-like information with fewer manual steps. The most valuable platforms are reducing sample preparation, minimizing pipetting, automating calibration and controls, and presenting a result in a format that can be acted on by non-laboratory personnel. This design philosophy is important because operator variability is one of the largest risks in decentralized testing. Companies that simplify the full workflow, not only the analytical reaction, can expand into a much wider range of care settings.

Compact molecular diagnostics are a major innovation area. Sample-to-answer systems that perform extraction, amplification, detection, and interpretation in a closed cartridge can provide molecular-level results near the patient. The strategic direction is toward multiplex respiratory panels, sexual health testing, hepatitis testing, and other applications where a same-visit result changes management. The first FDA-authorized point-of-care hepatitis C RNA test in 2024 demonstrated how decentralized molecular testing can collapse a multi-visit diagnostic pathway into a single encounter and improve linkage to treatment.

Multiplexing is also raising the value of respiratory testing. Clinicians often cannot distinguish influenza, COVID-19, RSV, and other respiratory infections on symptoms alone. Multi-analyte antigen and molecular tests can reduce sequential testing and support more targeted treatment. The challenge for manufacturers is to balance menu breadth, sensitivity, time to result, instrument cost, and reimbursement. High-complexity panels may be clinically attractive but economically difficult in low-volume offices, while simple combined tests can achieve broad adoption when they align with seasonal demand and pharmacy or urgent-care workflows.

Connectivity and informatics are becoming core product features. Hospitals need point-of-care devices to identify the patient and operator, transmit results automatically, enforce competency requirements, document quality control, and integrate with laboratory information systems and electronic health records. Enterprise buyers also want dashboards that can monitor hundreds or thousands of devices across multiple facilities. Cybersecurity, software validation, remote updates, and interoperability are therefore moving from optional features to procurement requirements.

Microfluidics, biosensors, and cartridge engineering are improving the economics of near-patient testing. Lower sample volumes are particularly important in pediatrics, neonatal care, oncology, and critical care. Integrated cartridges can reduce contamination risk and hands-on time, while electrochemical and optical biosensors can deliver quantitative results from capillary blood or other small specimens. The next innovation cycle will focus on broader test menus from a common analyzer, longer shelf life, ambient storage, and more resilient manufacturing of enzymes, membranes, antibodies, and molded consumables.

Home testing innovation is moving from single-event testing toward connected care pathways. Smartphone-assisted readers, digital instructions, telehealth linkage, automated reminders, and cloud-based result sharing can improve usability and follow-up. The market opportunity is strongest when home testing is embedded in a broader service model, such as chronic disease management, reproductive health, respiratory treatment access, or public health screening. Pure hardware differentiation will be difficult; consumer trust, retail distribution, data privacy, and post-result navigation will influence adoption.

Manufacturers are also raising the bar through evidence generation and quality management. U.S. purchasers increasingly expect analytical studies, clinical performance across diverse populations, interference testing, usability studies, real-world workflow data, and economic evidence. Health systems are cautious about introducing decentralized tests that create discordant results or manual documentation burdens. Products that demonstrate comparability to central laboratory methods, low invalid rates, stable quality-control performance, and measurable workflow improvement will be better positioned to defend premium pricing.

Segmentation Insights

The U.S. Point-of-Care Testing Devices Market is segmented on the basis of product category, technology platform, application, end user, and region. The 2025 market mix reflects a balance between high-volume recurring glucose and rapid-test consumables and higher-value molecular, blood gas, immunoassay, and connected analyzer systems.

By Product Category

Blood glucose monitoring devices represent the largest product category, accounting for an estimated USD 4.31 billion in 2025. This segment includes professional blood glucose meters, hospital-connected meters, strips, lancets, ketone testing products, and selected home-use systems used for treatment decisions. The segment benefits from daily or repeated testing frequency and a large installed base. Growth is slower than in molecular testing, but recurring consumable demand, device replacement, interoperability requirements, and the large diabetes population make it a durable revenue pool.
Infectious disease testing devices form the fastest-growing major product category and represented approximately USD 3.15 billion in 2025. The segment includes rapid antigen tests, reader-based immunoassays, compact molecular systems, respiratory panels, strep tests, HIV and hepatitis tests, STI platforms, and other decentralized infectious disease products. Growth is being driven by multiplex respiratory demand, CLIA-waived molecular testing, same-visit treatment, and the expansion of testing into urgent care, retail, community, and home settings.
Blood gas, electrolyte, and critical-care analyzers accounted for an estimated USD 2.05 billion in 2025. This category includes handheld and benchtop systems for blood gases, electrolytes, lactate, creatinine, ionized calcium, and related acute-care analytes. Demand is concentrated in emergency departments, intensive care units, operating rooms, neonatal care, cardiac care, transport medicine, and high-acuity ambulatory settings. Procurement is influenced by cartridge menu, sample volume, analyzer uptime, calibration automation, connectivity, and consistency with central laboratory results.
Cardiometabolic testing devices represented approximately USD 1.65 billion in 2025 and include cardiac marker assays, lipid testing, HbA1c analyzers, cholesterol systems, and selected renal or metabolic markers. The segment is strategically attractive because results can influence immediate triage or chronic disease management. Growth will be supported by compact immunoassay systems, higher-sensitivity formats, community screening, and the integration of cardiometabolic testing into primary-care and pharmacy workflows.
Coagulation testing devices generated an estimated USD 1.12 billion in 2025. The segment includes PT/INR systems, activated clotting time testing, and other near-patient coagulation tools used in anticoagulation clinics, cardiac procedures, surgery, emergency care, and home management. Although direct oral anticoagulants have reduced some routine INR testing demand, warfarin monitoring remains important, and procedural coagulation testing continues to support hospital volumes. Device reliability, strip stability, quality control, and reimbursement are central purchasing factors.
Pregnancy and fertility testing devices accounted for approximately USD 1.05 billion in 2025. This category includes home pregnancy tests, professional urine and serum pregnancy tests, ovulation prediction systems, and selected fertility-related diagnostics. The segment has a large retail and e-commerce component, while professional pregnancy testing remains embedded in emergency, imaging, surgical, and ambulatory workflows. Digital readers and app-connected fertility tools are expanding value, but price competition remains high in conventional visual-read products.
Urinalysis, hematology, drugs-of-abuse, fecal occult blood, and other point-of-care devices collectively represented approximately USD 1.27 billion in 2025. These products serve diverse settings including primary care, occupational health, emergency medicine, long-term care, community screening, and public health. Growth will be strongest in automated urine readers, compact hematology systems, toxicology screening, and multi-analyte platforms that reduce the need for send-out testing.

By Technology Platform

Electrochemical biosensor platforms are the largest technology segment because they support the enormous installed base of glucose and blood chemistry testing. These devices translate biochemical reactions into electrical signals and are valued for speed, low sample volume, portability, and scalable strip manufacturing. Future growth will depend on improved hematocrit correction, interference management, wireless connectivity, and broader multi-analyte sensing rather than on meter hardware alone.
Lateral-flow and visual-read immunoassays remain central to pregnancy, respiratory, infectious disease, and drugs-of-abuse testing. Their advantages are low cost, rapid results, room-temperature storage, and minimal equipment. Reader-based fluorescence and digital interpretation are improving sensitivity and reducing subjective visual errors. The segment will continue to generate high volumes, but manufacturers face intense price competition and must differentiate through multiplexing, usability, shelf life, and retail distribution.
Molecular amplification platforms are the fastest-growing technology segment and represented an estimated USD 2.35 billion in 2025. PCR, isothermal amplification, and other nucleic acid technologies offer higher analytical sensitivity and pathogen specificity than many antigen tests. Closed-cartridge systems are expanding into CLIA-waived environments and enabling same-visit decisions for respiratory infections, sexual health, and hepatitis. The main constraints are cartridge cost, instrument utilization, reimbursement, and the need to maintain acceptable turnaround time.
Clinical chemistry and immunochemistry platforms include compact analyzers for cardiac markers, HbA1c, lipids, inflammatory markers, and other quantitative assays. These systems are moving toward smaller footprints, automated calibration, barcode-based reagent management, and broader menus. They are attractive to physician offices, urgent care centers, and hospital departments that need quantitative results without sending specimens to the core laboratory.
Microfluidic, optical, and hybrid cartridge technologies form an emerging platform category. These systems integrate sample handling, reagent movement, detection, and interpretation within a disposable cartridge or chip. Their commercial potential is high because they can support multiple analytes from a small specimen and reduce operator steps. Adoption will depend on manufacturing yield, cartridge cost, shelf stability, and the ability to scale a clinically meaningful assay menu.

By Application

Diabetes and glycemic management is the largest application area. Point-of-care glucose testing supports inpatient insulin dosing, emergency triage, long-term care, physician office management, and self-testing. HbA1c devices add value by enabling same-visit assessment of longer-term glucose control. The application remains foundational to the market, although competition from continuous glucose monitoring is changing the mix of traditional fingerstick testing in some patient groups.
Respiratory and other infectious disease diagnosis is the fastest-growing application. Seasonal influenza, COVID-19, RSV, strep, sexually transmitted infections, hepatitis, HIV, and gastrointestinal pathogens create demand for rapid differentiation. The application benefits from strong clinical urgency and the availability of antiviral or antibiotic treatment pathways. Multiplex molecular and antigen products will capture increasing value as providers seek to avoid empirical treatment and repeat visits.
Acute and critical-care testing includes blood gases, electrolytes, lactate, creatinine, hemoglobin, coagulation, and selected emergency markers. These tests are embedded in time-sensitive workflows where transport to a central laboratory can delay treatment. Hospitals are willing to pay for reliable near-patient results when the device improves emergency department, operating room, intensive care, neonatal, or transport efficiency. Connectivity and quality-management requirements are especially stringent in this application.
Cardiometabolic and coagulation management includes cardiac marker testing, lipids, HbA1c, PT/INR, and related analytes used in triage and chronic care. The application is gaining importance in primary care and ambulatory settings because same-visit testing can support medication adjustment and improve patient engagement. Growth will be influenced by assay performance, reimbursement, and whether devices can generate results that clinicians trust without routine central-laboratory confirmation.
Women’s health, reproductive health, toxicology, urinalysis, and other applications create a broad secondary market. Pregnancy testing remains high volume, while fertility, sexual health, drugs-of-abuse, and urinary tract assessment are becoming more digitally enabled. These applications are attractive for retail and consumer channels, but professional adoption requires clear linkage to treatment, confirmatory pathways, and documentation.

By End User

Hospitals and health systems are the dominant end users, accounting for an estimated USD 5.47 billion in 2025. They use point-of-care devices across emergency departments, intensive care, operating rooms, labor and delivery, neonatal care, oncology, dialysis, inpatient wards, and ambulatory departments. Large systems frequently standardize devices across facilities and negotiate enterprise contracts that include instruments, consumables, middleware, service, training, and quality-management support. Their purchasing decisions have an outsized influence on market access.
Physician offices, urgent care centers, retail clinics, and pharmacies represented approximately USD 3.43 billion in 2025. These sites prioritize CLIA-waived operation, rapid turnaround, compact footprint, simple training, and predictable per-test economics. Respiratory, strep, pregnancy, glucose, HbA1c, lipid, and sexual health tests are particularly relevant. Growth will be strongest where testing is linked to a reimbursable visit or immediate treatment pathway.
Home care and self-testing represented approximately USD 3.07 billion in 2025 and are expected to be the fastest-growing end-user segment. This category includes glucose testing, pregnancy and fertility products, respiratory antigen tests, HIV self-tests, and other consumer-accessible diagnostics. Adoption is supported by retail availability, e-commerce, digital instructions, and familiarity with home testing. The segment also faces high sensitivity to price, brand trust, expiration management, and consumer interpretation.
Ambulatory surgery centers, long-term care facilities, dialysis centers, and post-acute providers represented approximately USD 1.53 billion in 2025. These sites require testing that supports pre-procedure screening, glucose management, coagulation assessment, infection control, and acute deterioration decisions. Devices must fit constrained staffing models and often need remote technical support, simplified quality control, and reliable supply availability.
Community health centers, public health programs, employer clinics, correctional health, emergency medical services, and mobile testing programs represented approximately USD 1.10 billion in 2025. These users are important for underserved populations, outbreak response, hepatitis and HIV screening, diabetes assessment, and rural access. Funding cycles can be variable, but decentralized platforms that reduce loss to follow-up and support immediate linkage to care have strong strategic value.

Regional Insights: Where the Market is Growing Fastest

The U.S. Point-of-Care Testing Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance varies according to population growth, diabetes and infectious disease burden, hospital and urgent-care density, state scope-of-practice rules, payer mix, rural access, pharmacy participation, academic medical center concentration, and the maturity of health-system connectivity. The South is the largest market in 2025, while the West is expected to record the fastest CAGR through 2035. The Northeast remains the most evidence-intensive and high-value region per site, and the Midwest provides a durable base of hospital and chronic disease testing demand.

South

The South is the largest regional market, accounting for an estimated USD 5.18 billion in 2025 and projected to reach approximately USD 12.83 billion by 2035, representing a CAGR of about 9.49%. The region includes Delaware, Maryland, the District of Columbia, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida, Kentucky, Tennessee, Mississippi, Alabama, Oklahoma, Texas, Arkansas, and Louisiana. Its leadership is supported by large population centers, rapid migration into several states, high diabetes and cardiometabolic burden, substantial rural access gaps, and expanding urgent-care and health-system networks.

Texas and Florida are the two most important state markets in the South. Texas had an estimated population of approximately 31.7 million in 2025 and combines major academic and integrated delivery networks in Houston, Dallas-Fort Worth, Austin, and San Antonio with large rural and border populations. This creates demand for both high-throughput hospital platforms and portable systems used in community care, emergency transport, and outpatient settings. Florida had an estimated 23.5 million residents in 2025 and a large older-adult population, supporting recurring glucose, coagulation, respiratory, cardiac, and long-term-care testing volumes.

North Carolina, Georgia, Virginia, Tennessee, and Maryland are high-priority growth markets. North Carolina and Georgia combine population expansion with strong academic health systems and growing urgent-care penetration. Virginia and Maryland benefit from dense provider networks, government and military healthcare activity, and large suburban markets. Tennessee has major hospital operators and distribution infrastructure that can accelerate enterprise purchasing. These states are well suited to connected systems that can be standardized across hospitals, physician practices, and retail or ambulatory locations.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, and West Virginia have elevated chronic disease burden and large rural or medically underserved populations. Point-of-care testing is strategically important in these states because specimen transport and central laboratory turnaround can be difficult outside major metropolitan areas. Community health centers, critical access hospitals, nursing facilities, and mobile programs create demand for glucose, HbA1c, respiratory, pregnancy, urinalysis, and infectious disease testing. Price sensitivity is higher, making reagent cost, distributor support, shelf life, and grant or public-health funding important commercial factors.

South Carolina, Delaware, and the District of Columbia are smaller in absolute market size but strategically distinct. South Carolina is benefiting from population growth and hospital expansion. Delaware has concentrated health-system purchasing and proximity to major Northeast markets. The District of Columbia supports high-acuity academic care, public health programs, and a large commuter population. Across the South, manufacturers that combine CLIA-waived menus, multilingual training, dependable distribution, and strong reimbursement support will have the best opportunity to expand penetration.

West

The West represented an estimated USD 3.43 billion in 2025 and is projected to reach approximately USD 9.22 billion by 2035, producing the fastest regional CAGR of about 10.39%. The region includes Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah, Nevada, Washington, Oregon, California, Alaska, and Hawaii. Growth is supported by technology-oriented health systems, large consumer diagnostics markets, rapid population expansion in selected states, rural distance challenges, and a strong concentration of diagnostic and digital-health innovation.

California is the largest state market in the West and had an estimated population of approximately 39.4 million in 2025. It contains major academic medical centers, integrated delivery networks, biotechnology and diagnostics companies, retail health channels, and diverse public-health needs. California is an early-adoption market for connected analyzers, digital home testing, compact molecular platforms, and data-driven quality management. However, buyers are highly evidence-focused, and vendors must address cybersecurity, interoperability, labor-saving economics, and environmental or supply-chain requirements.

Arizona, Nevada, Utah, and Colorado are among the fastest-growing state opportunities. Arizona and Nevada have expanding metropolitan populations and strong demand for urgent care, senior care, respiratory testing, and diabetes management. Utah has a sophisticated health-system and technology ecosystem, while Colorado combines large integrated networks with rural access requirements. These states favor scalable platforms that can be deployed across mixed urban and remote care settings.

Washington and Oregon are important for connected care, health-system standardization, and adoption of digitally managed testing. Their large provider organizations frequently evaluate enterprise interoperability, population health value, and environmental footprint. Idaho, Montana, Wyoming, New Mexico, and Alaska have lower absolute revenue but significant need for portable and low-maintenance devices because of long travel distances, workforce constraints, and limited access to central laboratories. Shelf stability, remote training, and service coverage are critical in these markets.

Hawaii has a small but distinctive market shaped by island logistics, military and tourism-related healthcare, and dependence on reliable supply chains. Across the West, point-of-care testing growth will be strongest in molecular respiratory testing, connected home diagnostics, diabetes and cardiometabolic monitoring, and compact systems that support rural and ambulatory care. The region will also remain an important launch market for venture-backed diagnostic platforms seeking early clinical validation.

Northeast

The Northeast accounted for an estimated USD 3.14 billion in 2025 and is projected to reach approximately USD 7.19 billion by 2035, expanding at a CAGR of about 8.64%. The region includes Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, and Pennsylvania. It has a high concentration of academic medical centers, teaching hospitals, specialty networks, dense urban care, and evidence-driven procurement. The region’s market value per site is high because of advanced testing menus, strong connectivity requirements, and frequent adoption of premium molecular and critical-care systems.

New York is the largest state market in the Northeast. Its demand is distributed across major academic centers, large integrated systems, community hospitals, physician networks, urgent care, retail health, and public-health programs. New York City supports high testing density and diverse infectious disease needs, while upstate areas require portable solutions for rural and community care. Vendors must be able to support enterprise-scale contracts and complex implementation across multiple facilities.

Massachusetts is highly influential because of its concentration of research institutions, teaching hospitals, diagnostics companies, and early-adopter clinicians. It is an important validation market for molecular, microfluidic, and digitally connected point-of-care systems. Pennsylvania and New Jersey provide large hospital and outpatient markets with strong demand for respiratory, cardiac, blood gas, diabetes, and pregnancy testing. New Jersey’s pharmaceutical and diagnostics ecosystem also supports commercial partnerships and distribution.

Connecticut and Rhode Island offer concentrated health-system markets where vendor standardization and connectivity can influence share quickly. Maine, New Hampshire, and Vermont are smaller but strategically relevant for rural health, aging populations, and regional hospital networks. In these states, point-of-care testing can reduce specimen transport and improve same-visit decision-making, but buyers require dependable service and cost control.

The Northeast is expected to grow slightly below the national average because it is a mature market with slower population growth. Nevertheless, it will remain highly profitable for manufacturers that can meet rigorous analytical, compliance, and informatics requirements. The region will continue to influence national adoption through clinical studies, laboratory leadership, and health-system value-analysis processes.

Midwest

The Midwest represented an estimated USD 2.85 billion in 2025 and is projected to reach approximately USD 5.96 billion by 2035, growing at a CAGR of about 7.66%. The region includes Ohio, Indiana, Illinois, Michigan, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota. Demand is supported by major academic and community hospital networks, a large base of chronic disease management, manufacturing and occupational health testing, and significant rural healthcare needs.

Illinois, Ohio, Michigan, and Minnesota are the principal state markets. Illinois benefits from Chicago’s dense hospital, physician, and urgent-care ecosystem. Ohio has several nationally recognized health systems and large procedure and emergency volumes. Michigan combines major urban systems with substantial chronic disease burden, while Minnesota is strategically important because of its medtech industry, integrated providers, and sophisticated laboratory leadership. These states are attractive for enterprise point-of-care connectivity and multi-site standardization.

Indiana, Wisconsin, and Missouri provide stable demand across hospitals, ambulatory settings, long-term care, and employer health. Their health systems often emphasize operational reliability, contracting discipline, and measurable labor savings. Iowa, Kansas, Nebraska, North Dakota, and South Dakota have smaller absolute markets but strong need for decentralized testing in critical access hospitals, rural clinics, emergency medical services, and community health programs.

The Midwest is less exposed to rapid population growth than the South and West, but it offers predictable utilization and durable installed bases. Manufacturers can succeed through service quality, distributor coverage, cost-effective reagent agreements, and clinical education. Devices that perform reliably across both large tertiary centers and low-volume rural sites will be especially well positioned.

Key Market Players

The U.S. Point-of-Care Testing Devices Competitive Landscape is moderately consolidated in core categories but remains fragmented across applications. Large global diagnostics companies control major installed bases in glucose, blood gas, immunoassay, molecular, and hospital connectivity. Specialized companies compete in lateral flow, HIV and hepatitis testing, compact chemistry, hematology, coagulation, consumer diagnostics, and single-use molecular systems. Competitive advantage depends on assay menu, installed-base scale, consumable economics, CLIA-waiver strategy, distribution reach, service capability, and informatics integration.

Competition is increasingly platform-based. Leading vendors seek to place a common analyzer across multiple departments or care settings and then expand recurring cartridge pull-through. Health systems favor vendors that can reduce the number of device types, simplify operator training, integrate with middleware, and provide centralized quality management. Smaller companies can still gain share by solving a specific workflow problem, such as instrument-free molecular testing, rapid STI diagnosis, compact HbA1c analysis, or high-performance respiratory multiplexing.

Some of the key players in the U.S. Point-of-Care Testing Devices industry are

Abbott Laboratories
Roche Diagnostics
Siemens Healthineers
Danaher Corporation
Cepheid
Radiometer Medical
HemoCue
QuidelOrtho Corporation
Becton, Dickinson and Company
bioMérieux
Thermo Fisher Scientific
Werfen
Nova Biomedical
Sekisui Diagnostics
OraSure Technologies
Trinity Biotech
EKF Diagnostics
ACON Laboratories
ARKRAY
LifeScan
Dexcom
i-SENS
Polymer Technology Systems
Visby Medical
Healgen Scientific

Abbott, Roche, Siemens Healthineers, Danaher, Cepheid, Radiometer, QuidelOrtho, BD, bioMérieux, and Werfen represent the strongest broad-platform competitors because of their established hospital relationships, assay portfolios, installed bases, and service infrastructure. Nova Biomedical, EKF Diagnostics, HemoCue, ARKRAY, LifeScan, Dexcom, and i-SENS are influential in glucose and compact blood analysis. OraSure, Trinity Biotech, Sekisui, ACON, Healgen, PTS Diagnostics, and Visby Medical support competition in infectious disease, respiratory, sexual health, cardiometabolic, and consumer testing.

Market share through 2035 will be influenced by FDA clearances, CLIA waivers, assay-menu expansion, instrument reliability, supply continuity, quality-control performance, reimbursement support, retail access, and data connectivity. Companies that can demonstrate lower invalid rates, faster treatment decisions, reduced repeat visits, and easier network management will be best positioned to maintain premium pricing.

Recent Developments

Recent developments in the U.S. Point-of-Care Testing Devices Market show a clear shift toward decentralized molecular testing and broader consumer access. In June 2024, the FDA granted marketing authorization for Cepheid’s Xpert HCV test and GeneXpert Xpress System, the first hepatitis C RNA test authorized for appropriately certified point-of-care settings. The development is strategically important because it enables active infection to be identified from a fingerstick specimen and can reduce loss to follow-up between antibody screening, confirmatory testing, and treatment initiation.

In July 2024, Roche completed the acquisition of LumiraDx’s point-of-care technology. The platform is designed to support multiple diagnostic modalities and complements Roche’s established clinical chemistry, immunochemistry, coagulation, and molecular capabilities. The transaction reflects the strategic value that large diagnostics companies place on primary-care and near-patient testing platforms with recurring consumable revenue.

In October 2024, the FDA granted traditional marketing authorization to the Healgen Rapid Check COVID-19/Flu A&B Antigen Test for over-the-counter home use. The test provides results in approximately 15 minutes and was the first home flu and COVID-19 combination test authorized through a conventional premarket pathway rather than only under an emergency use authorization. This development supports a more permanent consumer respiratory testing category beyond pandemic-era emergency policy.

In February 2025, Visby Medical received FDA clearance and a CLIA waiver for its point-of-care Respiratory Health Test for influenza A, influenza B, and SARS-CoV-2. The single-use molecular format illustrates the movement toward compact PCR testing that can be deployed in waived settings without a conventional laboratory instrument. Such products can be attractive to urgent care and physician offices when same-visit treatment decisions justify the per-test cost.

In 2026, QuidelOrtho completed the acquisition of LEX Diagnostics after the LEX VELO molecular system received FDA clearance and a CLIA waiver. The transaction highlights continuing consolidation around fast, decentralized molecular platforms and indicates that established diagnostics companies are using acquisition to shorten development timelines and expand next-generation point-of-care menus.

The market is also being reshaped by stricter attention to quality and post-market performance. Product recalls and regulatory actions in the home-testing segment have reinforced the importance of manufacturing controls, lot consistency, complaint handling, and clear consumer instructions. Over the forecast period, regulatory credibility and supply-chain execution will be as important as assay innovation.

Conclusion

The U.S. Point-of-Care Testing Devices Market Size & Share is positioned for sustained expansion from USD 14.60 billion in 2025 to approximately USD 35.20 billion by 2035, supported by a 9.20% CAGR during the forecast period. The market’s long-term strength is grounded in the scale of chronic and infectious disease, the economics of same-visit decision-making, the expansion of CLIA-waived testing, the migration of care into outpatient and home settings, and the growing requirement for connected diagnostic networks.

The most attractive growth opportunities will come from compact molecular diagnostics, multiplex respiratory testing, connected hospital glucose systems, blood gas and electrolyte platforms, point-of-care HbA1c and cardiometabolic testing, sexual health diagnostics, hepatitis testing, and digitally supported home testing. Mature categories such as visual-read pregnancy tests, conventional glucose strips, and basic lateral-flow assays will remain important, but value growth will increasingly depend on quantitative performance, connectivity, workflow simplification, and linkage to treatment.

Regional opportunity will be led by the South because of its population scale, chronic disease burden, and expanding provider networks. The West will record the fastest growth because of technology adoption, consumer diagnostics, and strong outpatient migration. The Northeast will remain the most demanding premium market for evidence and connectivity, while the Midwest will provide a stable installed-base opportunity supported by hospital networks and rural access needs. At the state level, California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, New Jersey, Massachusetts, North Carolina, Georgia, Arizona, Michigan, Minnesota, Washington, and Virginia will remain especially important for manufacturers and distributors.

For clients evaluating this market, the central question is not whether testing will continue to move closer to the patient. The more important questions are which assays can support immediate clinical action, which platforms can scale across decentralized networks, and which vendors can deliver reliable supply, reimbursement support, and quality management. Companies that combine analytically credible devices with workflow economics, informatics, and strong post-result care pathways will define the next decade of the U.S. point-of-care testing devices industry.

TABLE OF CONTENT

1. U.S. Point-of-Care Testing Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Point-of-Care Testing Device Manufacturers
1.6.2. Assay, Reagent, Cartridge, and Biosensor Suppliers
1.6.3. Component and Contract Manufacturing Organizations
1.6.4. Hospitals and Integrated Delivery Networks
1.6.5. Physician Offices, Urgent Care Centers, and Retail Clinics
1.6.6. Community Health Centers and Public Health Testing Networks
1.6.7. Pharmacies, Home Testing Providers, and Digital Health Platforms
1.6.8. Group Purchasing Organizations and Diagnostic Distributors
1.6.9. Payers, Regulators, Laboratory Directors, and Clinical Decision-Makers

What this section provides: This section defines the point-of-care testing device market boundary, study scope, methodology, assumptions, and stakeholder ecosystem so clients understand how the U.S. market is measured, segmented, and validated.

2. U.S. Point-of-Care Testing Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size and Growth Trajectory, 2021–2035
2.8. High-Growth Product and Application Areas
2.9. Priority Customer and Care-Setting Opportunities
2.10. Regional and State-Level Opportunity Snapshot

What this section provides: This section gives decision-makers a concise view of market size, growth direction, testing-volume drivers, competitive intensity, high-growth diagnostic categories, and priority commercial opportunities.

3. U.S. Point-of-Care Testing Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising Diabetes and Chronic Disease Burden
3.1.2. Expansion of Decentralized and Near-Patient Diagnostics
3.1.3. Growth of Urgent Care, Retail Clinic, and Community-Based Testing
3.1.4. Demand for Faster Emergency and Critical-Care Decision-Making
3.1.5. Expansion of CLIA-Waived Testing Platforms
3.1.6. Growth of Rapid Molecular and Multiplex Infectious Disease Testing
3.1.7. Increasing Adoption of Home and Self-Testing Devices
3.1.8. Hospital Focus on Turnaround Time and Clinical Workflow Efficiency

3.2. Restraints and Their Impact Analysis
3.2.1. Variability in Point-of-Care Test Accuracy and Performance
3.2.2. Operator Training and Quality-Control Requirements
3.2.3. Reimbursement and Coverage Variability
3.2.4. Competition from Central Laboratory Testing
3.2.5. Instrument, Cartridge, and Consumable Cost Pressure
3.2.6. Data Connectivity and Interoperability Limitations
3.2.7. Product Recall and Supply Reliability Risks

3.3. Opportunities and Their Impact Analysis
3.3.1. Multiplex Molecular Point-of-Care Testing
3.3.2. Pharmacy-Based and Retail Diagnostic Services
3.3.3. Home-Based Chronic Disease Monitoring
3.3.4. Rural, Tribal, and Medically Underserved Testing Programs
3.3.5. Artificial Intelligence and Connected Diagnostic Platforms
3.3.6. Emergency Medical Services and Mobile Testing
3.3.7. Employer, School, and Occupational Health Testing
3.3.8. Antimicrobial Stewardship and Rapid Pathogen Identification

3.4. Challenges and Their Impact Analysis
3.4.1. Maintaining Consistent Quality Across Decentralized Sites
3.4.2. Integrating Results with Laboratory and Hospital Information Systems
3.4.3. Managing Test Menu Expansion and Device Standardization
3.4.4. Demonstrating Economic Value Beyond Rapid Turnaround Time
3.4.5. Managing Cybersecurity and Patient Data Protection
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Hospital Capital Procurement Behavior Analysis
3.8. Point-of-Care Testing Program Governance Analysis
3.9. Impact of Care Migration Beyond Central Laboratories

What this section provides: This section explains the clinical, commercial, reimbursement, operational, and technological forces shaping demand, helping clients evaluate market opportunities, adoption barriers, and execution risks.

4. U.S. Point-of-Care Testing Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry

4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Point-of-Care Testing Device Manufacturing Ecosystem
4.6. Assay, Reagent, Cartridge, and Consumable Supply Analysis
4.7. Impact of Digitalization and Connected Diagnostics
4.8. Application & Innovation Landscape
4.9. FDA Regulatory Framework Analysis
4.10. CLIA Waiver and Laboratory Quality Framework
4.11. CMS Reimbursement and Coverage Landscape
4.12. Coding and Payment Pathway Analysis
4.13. Import/Export Restrictions & Tariff Impact
4.14. Government Initiatives and Public Health Testing Programs
4.15. Impact of Escalating Geopolitical Tensions
4.16. Hospital Value Analysis Committee Decision Framework
4.17. Point-of-Care Testing Committee and Laboratory Oversight Framework
4.18. Cybersecurity, Data Privacy, and Interoperability Analysis

What this section provides: This section gives clients a comprehensive view of regulation, CLIA requirements, reimbursement, pricing, supply chains, digital connectivity, quality oversight, and institutional procurement dynamics.

5. U.S. Point-of-Care Testing Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Blood Glucose Testing Devices
5.1.2.1. Blood Glucose Meters
5.1.2.2. Test Strips and Lancets
5.1.2.3. Hospital-Grade Connected Glucose Systems
5.1.2.4. Professional Diabetes Monitoring Platforms

5.1.3. Infectious Disease Testing Devices
5.1.3.1. Respiratory Infection Testing Devices
5.1.3.2. COVID-19 Testing Devices
5.1.3.3. Influenza Testing Devices
5.1.3.4. Group A Streptococcus Testing Devices
5.1.3.5. Respiratory Syncytial Virus Testing Devices
5.1.3.6. HIV Testing Devices
5.1.3.7. Hepatitis Testing Devices
5.1.3.8. Sexually Transmitted Infection Testing Devices
5.1.3.9. Other Infectious Disease Testing Devices

5.1.4. Blood Gas and Electrolyte Testing Devices
5.1.4.1. Blood Gas Analyzers
5.1.4.2. Electrolyte Analyzers
5.1.4.3. Blood Gas and Electrolyte Cartridges
5.1.4.4. Critical-Care Chemistry Testing Systems

5.1.5. Cardiac Marker Testing Devices
5.1.5.1. Troponin Testing Devices
5.1.5.2. BNP and NT-proBNP Testing Devices
5.1.5.3. D-Dimer Testing Devices
5.1.5.4. Multi-Marker Cardiac Testing Platforms

5.1.6. Coagulation Testing Devices
5.1.6.1. PT/INR Testing Devices
5.1.6.2. Activated Clotting Time Testing Devices
5.1.6.3. Viscoelastic Coagulation Testing Systems
5.1.6.4. Coagulation Test Strips and Cartridges

5.1.7. Pregnancy and Fertility Testing Devices
5.1.7.1. Pregnancy Testing Devices
5.1.7.2. Ovulation and Fertility Testing Devices
5.1.7.3. Digital Reproductive Health Testing Devices

5.1.8. Hematology Testing Devices
5.1.8.1. Hemoglobin Testing Devices
5.1.8.2. Hematocrit Testing Devices
5.1.8.3. Complete Blood Count Point-of-Care Analyzers
5.1.8.4. Sickle Cell and Hemoglobinopathy Testing Devices

5.1.9. Urinalysis and Renal Testing Devices
5.1.9.1. Urine Chemistry Testing Devices
5.1.9.2. Albumin and Creatinine Testing Devices
5.1.9.3. Kidney Function Testing Devices
5.1.9.4. Urinary Tract Infection Testing Devices

5.1.10. Drugs-of-Abuse and Toxicology Testing Devices
5.1.10.1. Urine-Based Testing Devices
5.1.10.2. Oral Fluid Testing Devices
5.1.10.3. Multi-Panel Toxicology Testing Devices
5.1.10.4. Occupational and Forensic Testing Devices

5.1.11. Other Point-of-Care Testing Devices
5.1.11.1. Cholesterol and Lipid Testing Devices
5.1.11.2. HbA1c Testing Devices
5.1.11.3. Inflammatory Marker Testing Devices
5.1.11.4. Fecal Occult Blood Testing Devices
5.1.11.5. Cancer Marker Testing Devices
5.1.11.6. Other Specialty Testing Devices

What this section provides: This section identifies the point-of-care testing product categories expected to generate the largest revenue contribution, recurring consumable demand, and strongest growth through 2035.

6. U.S. Point-of-Care Testing Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Diabetes and Metabolic Disease Management
6.1.3. Infectious Disease Diagnosis
6.1.4. Cardiovascular and Cardiac Emergency Assessment
6.1.5. Critical-Care and Emergency Medicine
6.1.6. Coagulation and Anticoagulation Management
6.1.7. Pregnancy, Fertility, and Women’s Health
6.1.8. Renal Disease and Urinary Tract Assessment
6.1.9. Hematology and Anemia Screening
6.1.10. Toxicology and Drugs-of-Abuse Screening
6.1.11. Gastrointestinal Disease Testing
6.1.12. Occupational and Employee Health Screening
6.1.13. Other Clinical Applications

What this section provides: This section helps clients understand demand by clinical use case and prioritize applications with high testing frequency, rapid-decision requirements, reimbursement relevance, and strong device innovation.

7. U.S. Point-of-Care Testing Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Hospitals and Integrated Health Systems
7.1.2.1. Emergency Departments
7.1.2.2. Intensive Care Units
7.1.2.3. Operating Rooms and Procedural Departments
7.1.2.4. Inpatient Nursing Units
7.1.2.5. Hospital Outpatient Departments

7.1.3. Physician Offices and Specialty Practices
7.1.3.1. Primary Care Practices
7.1.3.2. Endocrinology and Diabetes Practices
7.1.3.3. Cardiology Practices
7.1.3.4. Obstetrics and Gynecology Practices
7.1.3.5. Infectious Disease and Other Specialty Practices

7.1.4. Urgent Care Centers and Walk-In Clinics
7.1.5. Diagnostic Laboratories and Reference Laboratory Networks
7.1.6. Community Health Centers and Federally Qualified Health Centers
7.1.7. Pharmacies and Retail Clinics
7.1.8. Ambulatory Surgery Centers
7.1.9. Emergency Medical Services and Mobile Care Providers
7.1.10. Home Healthcare and Self-Testing Users
7.1.11. Nursing Homes and Long-Term Care Facilities
7.1.12. Employer, School, Correctional, and Occupational Health Settings

What this section provides: This section explains which care settings and customer groups are expected to drive device purchasing, test utilization, recurring consumable demand, and decentralized diagnostic adoption.

8. U.S. Point-of-Care Testing Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Lateral Flow Immunoassay
8.1.3. Molecular Diagnostics
8.1.3.1. Polymerase Chain Reaction
8.1.3.2. Isothermal Nucleic Acid Amplification
8.1.3.3. CRISPR-Based and Emerging Molecular Methods
8.1.3.4. Multiplex Syndromic Testing

8.1.4. Electrochemical and Biosensor-Based Testing
8.1.5. Immunoassay Analyzer Technology
8.1.6. Microfluidics and Lab-on-a-Chip Technology
8.1.7. Optical and Spectrophotometric Testing
8.1.8. Dipstick and Visual Interpretation Technology
8.1.9. Digital and Smartphone-Connected Testing
8.1.10. Artificial Intelligence-Assisted Point-of-Care Testing
8.1.11. Other Emerging Technologies

What this section provides: This section evaluates the diagnostic technologies shaping market competition, including lateral flow, molecular testing, biosensors, microfluidics, digital connectivity, and AI-supported interpretation.

9. U.S. Point-of-Care Testing Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Direct Hospital and Health System Procurement
9.1.3. Integrated Delivery Network Enterprise Contracts
9.1.4. Group Purchasing Organization Contracts
9.1.5. Diagnostic Distributor and Specialty Supplier Sales
9.1.6. Physician Office and Urgent Care Procurement
9.1.7. Pharmacy and Retail Distribution
9.1.8. E-Commerce and Direct-to-Consumer Channels
9.1.9. Public Health, Federal, State, and Local Government Procurement
9.1.10. Employer and Occupational Health Contracts

What this section provides: This section explains how point-of-care testing devices, instruments, cartridges, reagents, and self-testing products are purchased across institutional, outpatient, retail, government, and direct-to-consumer channels.

10. U.S. Point-of-Care Testing Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Testing Volume and Healthcare Infrastructure Analysis
10.1.4. Regional CLIA-Waived Testing Site Analysis
10.1.5. Regional Disease Burden and Diagnostic Demand Analysis
10.1.6. Regional Reimbursement and Procurement Dynamics
10.1.7. Regional Hospital, Urgent Care, Pharmacy, and Community Testing Analysis

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Point-of-Care Testing Device Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Point-of-Care Testing Device Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Point-of-Care Testing Device Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Point-of-Care Testing Device Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level analysis, helping clients identify diagnostic demand centers, CLIA-waived testing density, hospital and urgent-care testing hubs, chronic disease hotspots, and state-level commercial opportunities.

11. U.S. Point-of-Care Testing Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players
11.3. Company Profiles
11.3.1. Abbott Laboratories
11.3.2. Roche Diagnostics
11.3.3. Siemens Healthineers
11.3.4. Danaher Corporation
11.3.5. Cepheid
11.3.6. QuidelOrtho Corporation
11.3.7. Becton, Dickinson and Company
11.3.8. bioMérieux
11.3.9. Nova Biomedical
11.3.10. Werfen
11.3.11. EKF Diagnostics Holdings
11.3.12. Trinity Biotech
11.3.13. OraSure Technologies
11.3.14. Thermo Fisher Scientific
11.3.15. Bio-Rad Laboratories
11.3.16. Sysmex Corporation
11.3.17. Sekisui Diagnostics
11.3.18. ARKRAY
11.3.19. ACON Laboratories
11.3.20. Polymer Technology Systems
11.3.21. i-SENS
11.3.22. QIAGEN
11.3.23. Visby Medical
11.3.24. binx health
11.3.25. SD Biosensor

Note: Each company profile will include company overview, point-of-care testing portfolio, U.S. market strategy, financial positioning, installed instrument base, assay menu, regulatory updates, distribution partnerships, product launches, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market share visibility, product portfolio positioning, installed-base analysis, innovation direction, and strategic intelligence on leading point-of-care testing companies.

12. U.S. Point-of-Care Testing Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario

12.2. Disruptive Technologies Impact
12.2.1. Multiplex Molecular Point-of-Care Platforms
12.2.2. Isothermal and CRISPR-Based Testing Technologies
12.2.3. Microfluidic and Lab-on-a-Chip Platforms
12.2.4. Artificial Intelligence-Assisted Result Interpretation
12.2.5. Smartphone-Connected Diagnostic Devices
12.2.6. Connected Home Testing and Remote Patient Monitoring
12.2.7. Non-Invasive and Minimally Invasive Biosensors
12.2.8. Automated Quality Control and Device Management Software

12.3. Emerging Business Trends
12.3.1. Care Migration to Retail and Community Settings
12.3.2. Expansion of Consumer-Directed Diagnostic Testing
12.3.3. Instrument Placement and Reagent Rental Models
12.3.4. Subscription-Based Testing and Digital Diagnostic Services
12.3.5. Consolidation of Point-of-Care Testing Platforms
12.3.6. Integrated Instrument, Assay, Software, and Data Ecosystems

12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Product and Application Opportunity Heatmap
12.7. Regional Expansion Opportunity Matrix
12.8. Forecast Risk and Sensitivity Analysis

What this section provides: This section prepares clients for future technology shifts, decentralized testing models, market structure changes, investment opportunities, and alternative adoption scenarios through 2035.

13. U.S. Point-of-Care Testing Devices Market: Strategic Recommendations

13.1. Recommendations for Point-of-Care Testing Device Manufacturers
13.2. Recommendations for Hospitals and Integrated Health Systems
13.3. Recommendations for Physician Offices and Urgent Care Operators
13.4. Recommendations for Pharmacies and Retail Clinic Networks
13.5. Recommendations for Community Health and Public Health Organizations
13.6. Recommendations for Investors and Private Equity Firms
13.7. Recommendations for Distributors and Channel Partners
13.8. Recommendations for New Entrants and Diagnostic Startups
13.9. Go-to-Market Strategy Considerations
13.10. Product Positioning and Assay Menu Expansion Guidance
13.11. CLIA-Waiver and Regulatory Strategy Considerations
13.12. Reimbursement and Health Economic Evidence Strategy
13.13. Hospital and IDN Contracting Recommendations
13.14. Digital Connectivity and Data Integration Strategy
13.15. State-Level Commercial Expansion Priorities

What this section provides: This section converts market intelligence into actionable recommendations for product development, market entry, assay expansion, regulatory planning, channel growth, contracting, and competitive differentiation.

14. U.S. Point-of-Care Testing Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer
14.6. Regulatory and Reimbursement Information Disclaimer
14.7. Company and Competitive Intelligence Disclaimer

What this section provides: This section clarifies the report’s analytical limitations, legal boundaries, data-use conditions, forecasting assumptions, and treatment of third-party, regulatory, reimbursement, and company information.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Point-of-Care Testing Devices Market: Market Definition and Scope
TABLE 3: U.S. Point-of-Care Testing Devices Market: Research Methodology Framework
TABLE 4: U.S. Point-of-Care Testing Devices Market: Key Assumptions
TABLE 5: U.S. Point-of-Care Testing Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Point-of-Care Testing Devices Market: Stakeholder Analysis
TABLE 7: U.S. Point-of-Care Testing Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Point-of-Care Testing Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Point-of-Care Testing Devices Market: Market Attractiveness Index
TABLE 10: U.S. Point-of-Care Testing Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Point-of-Care Testing Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Point-of-Care Testing Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. Point-of-Care Testing Devices Market: Drivers; Impact Analysis
TABLE 14: U.S. Point-of-Care Testing Devices Market: Restraints; Impact Analysis
TABLE 15: U.S. Point-of-Care Testing Devices Market: Opportunities; Impact Analysis
TABLE 16: U.S. Point-of-Care Testing Devices Market: Challenges; Impact Analysis
TABLE 17: U.S. Point-of-Care Testing Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 18: U.S. Point-of-Care Testing Devices Market: Clinical Workflow Economics Matrix
TABLE 19: U.S. Point-of-Care Testing Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 20: U.S. Point-of-Care Testing Devices Market: PESTEL Analysis
TABLE 21: U.S. Point-of-Care Testing Devices Market: Porter’s Five Forces Analysis
TABLE 22: U.S. Point-of-Care Testing Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 23: U.S. Point-of-Care Testing Devices Market: Value Chain Analysis
TABLE 24: U.S. Point-of-Care Testing Devices Market: Supply Chain Analysis
TABLE 25: U.S. Point-of-Care Testing Devices Market: Digitalization and Connected Diagnostics Impact
TABLE 26: U.S. Point-of-Care Testing Devices Market: Application & Innovation Landscape
TABLE 27: U.S. Point-of-Care Testing Devices Market: FDA Regulatory Framework Analysis
TABLE 28: U.S. Point-of-Care Testing Devices Market: CLIA Waiver and Laboratory Quality Framework
TABLE 29: U.S. Point-of-Care Testing Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 30: U.S. Point-of-Care Testing Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 31: U.S. Point-of-Care Testing Devices Market: Government Initiatives and Public Health Testing Programs
TABLE 32: U.S. Point-of-Care Testing Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 33: U.S. Point-of-Care Testing Devices Market: Product Type Snapshot, 2025
TABLE 34: Segment Dashboard; Definition and Scope, by Product Type
TABLE 35: U.S. Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 36: U.S. Point-of-Care Testing Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 37: U.S. Point-of-Care Testing Devices Market: Glucose, HbA1c and Metabolic Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 38: U.S. Point-of-Care Testing Devices Market: Infectious Disease Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 39: U.S. Point-of-Care Testing Devices Market: Blood Gas, Electrolyte and Critical-Care Chemistry Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 40: U.S. Point-of-Care Testing Devices Market: Cardiac Marker and Coagulation Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 41: U.S. Point-of-Care Testing Devices Market: Pregnancy, Fertility, Hematology, Urinalysis, Toxicology and Other Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 42: U.S. Point-of-Care Testing Devices Market: Application Snapshot, 2025
TABLE 43: Segment Dashboard; Definition and Scope, by Application
TABLE 44: U.S. Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 45: U.S. Point-of-Care Testing Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 46: U.S. Point-of-Care Testing Devices Market: Diabetes and Metabolic Disease Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Point-of-Care Testing Devices Market: Infectious Disease Diagnosis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Point-of-Care Testing Devices Market: Cardiac, Coagulation and Critical-Care Assessment Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. Point-of-Care Testing Devices Market: Women’s Health, Hematology and Renal Assessment Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. Point-of-Care Testing Devices Market: Toxicology, Occupational Health and Other Clinical Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. Point-of-Care Testing Devices Market: End User Snapshot, 2025
TABLE 52: Segment Dashboard; Definition and Scope, by End User
TABLE 53: U.S. Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 54: U.S. Point-of-Care Testing Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 55: U.S. Point-of-Care Testing Devices Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Point-of-Care Testing Devices Market: Physician Offices, Specialty Practices and Urgent Care Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Point-of-Care Testing Devices Market: Diagnostic Laboratories, Community Health Centers and FQHCs Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Point-of-Care Testing Devices Market: Pharmacies, Retail Clinics and Ambulatory Care Settings Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. Point-of-Care Testing Devices Market: Home Healthcare, Long-Term Care, EMS and Occupational Health Settings Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Point-of-Care Testing Devices Market: Technology Type Snapshot, 2025
TABLE 61: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 62: U.S. Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 63: U.S. Point-of-Care Testing Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 64: U.S. Point-of-Care Testing Devices Market: Lateral Flow Immunoassay Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Point-of-Care Testing Devices Market: Molecular Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Point-of-Care Testing Devices Market: Electrochemical and Biosensor-Based Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. Point-of-Care Testing Devices Market: Immunoassay, Microfluidic and Optical Testing Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. Point-of-Care Testing Devices Market: Digital, Smartphone-Connected and AI-Assisted Testing Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. Point-of-Care Testing Devices Market: Procurement Channel Snapshot, 2025
TABLE 70: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 71: U.S. Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 72: U.S. Point-of-Care Testing Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 73: U.S. Point-of-Care Testing Devices Market: Direct Hospital and Integrated Delivery Network Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Point-of-Care Testing Devices Market: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Point-of-Care Testing Devices Market: Diagnostic Distributor and Specialty Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Point-of-Care Testing Devices Market: Physician Office, Urgent Care, Pharmacy and Retail Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. Point-of-Care Testing Devices Market: E-Commerce, Government and Employer Contract Channels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: U.S. Point-of-Care Testing Devices Market: Regional Snapshot, 2025
TABLE 79: Segment Dashboard; Definition and Scope, by Region
TABLE 80: U.S. Point-of-Care Testing Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 81: U.S. Point-of-Care Testing Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 82: West Region U.S. Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 83: West Region U.S. Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 84: West Region U.S. Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 85: West Region U.S. Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 86: West Region U.S. Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 87: West Region U.S. Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 88: West Region U.S. Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 89: West Region U.S. Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 90: California Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 91: California Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 92: California Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 93: California Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 94: California Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 95: Washington Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 96: Washington Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 97: Washington Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 98: Washington Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 99: Washington Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 100: Arizona Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 101: Arizona Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 102: Arizona Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 103: Arizona Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 104: Arizona Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 105: Colorado Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 106: Colorado Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 107: Colorado Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 108: Colorado Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 109: Colorado Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 110: Oregon Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 111: Oregon Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 112: Oregon Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 113: Oregon Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 114: Oregon Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 115: Utah Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 116: Utah Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 117: Utah Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 118: Utah Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 119: Utah Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 120: Nevada Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 121: Nevada Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 122: Nevada Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 123: Nevada Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 124: Nevada Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 125: New Mexico Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 126: New Mexico Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 127: New Mexico Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 128: New Mexico Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 129: New Mexico Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 130: Idaho Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 131: Idaho Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 132: Idaho Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 133: Idaho Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 134: Idaho Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 135: Montana Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 136: Montana Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 137: Montana Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 138: Montana Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 139: Montana Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 140: Wyoming Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 141: Wyoming Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 142: Wyoming Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 143: Wyoming Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 144: Wyoming Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 145: Alaska Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 146: Alaska Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 147: Alaska Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 148: Alaska Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 149: Alaska Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 150: Hawaii Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 151: Hawaii Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 152: Hawaii Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 153: Hawaii Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 154: Hawaii Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 155: Northeast Region U.S. Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 156: Northeast Region U.S. Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 157: Northeast Region U.S. Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 158: Northeast Region U.S. Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 159: Northeast Region U.S. Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 160: Northeast Region U.S. Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 161: Northeast Region U.S. Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 162: Northeast Region U.S. Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 163: New York Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 164: New York Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 165: New York Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 166: New York Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 167: New York Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 168: Massachusetts Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 169: Massachusetts Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 170: Massachusetts Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 171: Massachusetts Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 172: Massachusetts Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 173: New Jersey Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 174: New Jersey Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 175: New Jersey Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 176: New Jersey Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 177: New Jersey Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 178: Pennsylvania Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 179: Pennsylvania Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 180: Pennsylvania Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 181: Pennsylvania Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 182: Pennsylvania Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 183: Connecticut Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 184: Connecticut Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 185: Connecticut Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 186: Connecticut Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 187: Connecticut Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 188: Maine Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 189: Maine Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 190: Maine Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 191: Maine Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 192: Maine Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 193: Vermont Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 194: Vermont Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 195: Vermont Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 196: Vermont Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 197: Vermont Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 198: New Hampshire Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 199: New Hampshire Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 200: New Hampshire Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 201: New Hampshire Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 202: New Hampshire Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 203: Rhode Island Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 204: Rhode Island Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 205: Rhode Island Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 206: Rhode Island Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 207: Rhode Island Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 208: Delaware Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 209: Delaware Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 210: Delaware Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 211: Delaware Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 212: Delaware Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 213: South Region U.S. Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 214: South Region U.S. Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 215: South Region U.S. Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 216: South Region U.S. Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 217: South Region U.S. Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 218: South Region U.S. Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 219: South Region U.S. Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 220: South Region U.S. Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 221: Texas Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 222: Texas Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 223: Texas Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 224: Texas Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 225: Texas Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 226: Florida Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 227: Florida Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 228: Florida Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 229: Florida Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 230: Florida Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 231: Georgia Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 232: Georgia Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 233: Georgia Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 234: Georgia Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 235: Georgia Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 236: North Carolina Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 237: North Carolina Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 238: North Carolina Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 239: North Carolina Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 240: North Carolina Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 241: Tennessee Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 242: Tennessee Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 243: Tennessee Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 244: Tennessee Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 245: Tennessee Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 246: South Carolina Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 247: South Carolina Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 248: South Carolina Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 249: South Carolina Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 250: South Carolina Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 251: Alabama Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 252: Alabama Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 253: Alabama Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 254: Alabama Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 255: Alabama Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 256: Mississippi Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 257: Mississippi Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 258: Mississippi Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 259: Mississippi Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 260: Mississippi Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 261: Louisiana Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 262: Louisiana Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 263: Louisiana Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 264: Louisiana Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 265: Louisiana Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 266: Arkansas Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 267: Arkansas Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 268: Arkansas Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 269: Arkansas Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 270: Arkansas Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 271: Kentucky Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 272: Kentucky Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 273: Kentucky Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 274: Kentucky Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 275: Kentucky Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 276: Oklahoma Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 277: Oklahoma Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 278: Oklahoma Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 279: Oklahoma Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 280: Oklahoma Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 281: Virginia Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 282: Virginia Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 283: Virginia Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 284: Virginia Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 285: Virginia Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 286: Maryland Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 287: Maryland Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 288: Maryland Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 289: Maryland Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 290: Maryland Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 291: West Virginia Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 292: West Virginia Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 293: West Virginia Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 294: West Virginia Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 295: West Virginia Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 296: Midwest Region U.S. Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 297: Midwest Region U.S. Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 298: Midwest Region U.S. Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 299: Midwest Region U.S. Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 300: Midwest Region U.S. Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 301: Midwest Region U.S. Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 302: Midwest Region U.S. Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 303: Midwest Region U.S. Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 304: Illinois Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 305: Illinois Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 306: Illinois Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 307: Illinois Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 308: Illinois Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 309: Ohio Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 310: Ohio Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 311: Ohio Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 312: Ohio Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 313: Ohio Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 314: Michigan Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 315: Michigan Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 316: Michigan Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 317: Michigan Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 318: Michigan Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 319: Minnesota Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 320: Minnesota Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 321: Minnesota Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 322: Minnesota Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 323: Minnesota Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 324: Indiana Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 325: Indiana Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 326: Indiana Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 327: Indiana Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 328: Indiana Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 329: Wisconsin Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 330: Wisconsin Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 331: Wisconsin Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 332: Wisconsin Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 333: Wisconsin Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 334: Missouri Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 335: Missouri Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 336: Missouri Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 337: Missouri Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 338: Missouri Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 339: Iowa Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 340: Iowa Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 341: Iowa Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 342: Iowa Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 343: Iowa Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 344: Kansas Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 345: Kansas Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 346: Kansas Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 347: Kansas Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 348: Kansas Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 349: Nebraska Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 350: Nebraska Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 351: Nebraska Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 352: Nebraska Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 353: Nebraska Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 354: North Dakota Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 355: North Dakota Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 356: North Dakota Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 357: North Dakota Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 358: North Dakota Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 359: South Dakota Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 360: South Dakota Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 361: South Dakota Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 362: South Dakota Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 363: South Dakota Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 364: U.S. Point-of-Care Testing Devices Market: Competitive Landscape Snapshot, 2025
TABLE 365: U.S. Point-of-Care Testing Devices Market: Key Company Market Share Analysis, 2025
TABLE 366: U.S. Point-of-Care Testing Devices Market: Company Positioning Matrix
TABLE 367: U.S. Point-of-Care Testing Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 368: U.S. Point-of-Care Testing Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 369: Abbott Laboratories: Company Profile
TABLE 370: Roche Diagnostics: Company Profile
TABLE 371: Siemens Healthineers: Company Profile
TABLE 372: Danaher Corporation: Company Profile
TABLE 373: Cepheid: Company Profile
TABLE 374: QuidelOrtho Corporation: Company Profile
TABLE 375: Becton, Dickinson and Company: Company Profile
TABLE 376: bioMérieux: Company Profile
TABLE 377: Nova Biomedical: Company Profile
TABLE 378: Werfen: Company Profile
TABLE 379: EKF Diagnostics Holdings: Company Profile
TABLE 380: Trinity Biotech: Company Profile
TABLE 381: OraSure Technologies: Company Profile
TABLE 382: Thermo Fisher Scientific: Company Profile
TABLE 383: Bio-Rad Laboratories: Company Profile
TABLE 384: Sysmex Corporation: Company Profile
TABLE 385: Sekisui Diagnostics: Company Profile
TABLE 386: ARKRAY: Company Profile
TABLE 387: ACON Laboratories: Company Profile
TABLE 388: Polymer Technology Systems: Company Profile
TABLE 389: i-SENS: Company Profile
TABLE 390: QIAGEN: Company Profile
TABLE 391: Visby Medical: Company Profile
TABLE 392: binx health: Company Profile
TABLE 393: SD Biosensor: Company Profile
TABLE 394: U.S. Point-of-Care Testing Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 395: U.S. Point-of-Care Testing Devices Market: Disruptive Technologies Impact Matrix
TABLE 396: U.S. Point-of-Care Testing Devices Market: Emerging Business Trends
TABLE 397: U.S. Point-of-Care Testing Devices Market: Business Opportunities for Startups and Existing Players
TABLE 398: U.S. Point-of-Care Testing Devices Market: Investment Prioritization Matrix
TABLE 399: U.S. Point-of-Care Testing Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 400: U.S. Point-of-Care Testing Devices Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 401: U.S. Point-of-Care Testing Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 402: U.S. Point-of-Care Testing Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 403: U.S. Point-of-Care Testing Devices Market: Strategic Recommendations for New Entrants and Diagnostic Startups
TABLE 404: U.S. Point-of-Care Testing Devices Market: Go-to-Market Strategy Considerations
TABLE 405: U.S. Point-of-Care Testing Devices Market: Product Positioning and Assay Menu Expansion Guidance
TABLE 406: U.S. Point-of-Care Testing Devices Market: Scope Limitation
TABLE 407: U.S. Point-of-Care Testing Devices Market: Data Use Limitation
TABLE 408: U.S. Point-of-Care Testing Devices Market: Forecasting Limitation
TABLE 409: U.S. Point-of-Care Testing Devices Market: Legal Disclaimer
TABLE 410: U.S. Point-of-Care Testing Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Point-of-Care Testing Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: Supply Chain Analysis
FIGURE 5: PESTEL Analysis
FIGURE 6: Porter’s Five Forces Analysis
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Clinical Workflow Economics Framework
FIGURE 11: Hospital Capital Procurement Decision Framework
FIGURE 12: U.S. Point-of-Care Testing Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 13: U.S. Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 14: U.S. Point-of-Care Testing Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 15: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 16: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 17: Glucose, HbA1c and Metabolic Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 18: Infectious Disease Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Blood Gas, Electrolyte and Critical-Care Chemistry Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Cardiac Marker and Coagulation Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Pregnancy, Fertility, Hematology, Urinalysis, Toxicology and Other Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 23: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Diabetes and Metabolic Disease Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Infectious Disease Diagnosis Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Cardiac, Coagulation and Critical-Care Assessment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Women’s Health, Hematology and Renal Assessment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Toxicology, Occupational Health and Other Clinical Applications Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 30: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Physician Offices, Specialty Practices and Urgent Care Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Diagnostic Laboratories, Community Health Centers and FQHCs Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Pharmacies, Retail Clinics and Ambulatory Care Settings Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Home Healthcare, Long-Term Care, EMS and Occupational Health Settings Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 37: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Lateral Flow Immunoassay Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Molecular Diagnostics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Electrochemical and Biosensor-Based Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Immunoassay, Microfluidic and Optical Testing Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Digital, Smartphone-Connected and AI-Assisted Testing Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 44: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Direct Hospital and Integrated Delivery Network Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Diagnostic Distributor and Specialty Supplier Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Physician Office, Urgent Care, Pharmacy and Retail Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: E-Commerce, Government and Employer Contract Channels Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 51: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: West Region U.S. Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 53: West Region Market Share Analysis by State, 2025
FIGURE 54: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: California Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Washington Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Arizona Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Colorado Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Oregon Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Utah Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Nevada Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: New Mexico Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Idaho Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Montana Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Wyoming Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Alaska Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Hawaii Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Northeast Region U.S. Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 69: Northeast Region Market Share Analysis by State, 2025
FIGURE 70: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: New York Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Massachusetts Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New Jersey Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Pennsylvania Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Connecticut Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Maine Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Vermont Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: New Hampshire Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Rhode Island Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Delaware Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: South Region U.S. Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 82: South Region Market Share Analysis by State, 2025
FIGURE 83: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Texas Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Florida Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Georgia Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: North Carolina Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Tennessee Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: South Carolina Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Alabama Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Mississippi Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Louisiana Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Arkansas Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Kentucky Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Oklahoma Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Virginia Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Maryland Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: West Virginia Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Midwest Region U.S. Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 100: Midwest Region Market Share Analysis by State, 2025
FIGURE 101: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Illinois Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Ohio Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Michigan Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Minnesota Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Indiana Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Wisconsin Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Missouri Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Iowa Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Kansas Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Nebraska Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: North Dakota Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: South Dakota Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 115: Company Positioning Matrix
FIGURE 116: Key Player Product Portfolio Benchmarking
FIGURE 117: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 118: Point-of-Care Testing Device Innovation Roadmap
FIGURE 119: Multiplex Molecular Point-of-Care Testing Adoption Roadmap
FIGURE 120: Microfluidics and Lab-on-a-Chip Technology Opportunity Map
FIGURE 121: Connected Home Testing Growth Roadmap
FIGURE 122: Future Market Scenario Analysis, 2026–2035
FIGURE 123: Disruptive Technologies Impact Matrix
FIGURE 124: Emerging Business Trends Matrix
FIGURE 125: Investment Prioritization Matrix
FIGURE 126: Strategic Growth Roadmap for U.S. Point-of-Care Testing Device Companies
FIGURE 127: Go-to-Market Strategy Framework
FIGURE 128: Product Positioning and Assay Menu Expansion Framework
FIGURE 129: Report Scope and Disclaimer Framework